PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

EJNMMI Research

Table 7 Multivariable analysis for the association of baseline factors with BCR-free survival

	No. of patients	Hazard ratio	95% CI	p value*
Clinical data
Age, no., n = 186
Continuous		1.030	0.991–1.071	0.133
iPSA, no., n = 184
Continuous		1.024	1.005–1.043	0.014
Pathological data
Gleason score in surgical specimen, no., n = 186
6–7	133	Reference
8–10	53	3.253	1.779–5.950	< 0.001
pT status, no., n = 186
2	92	Reference
3	94	1.471	0.773–2.797	0.239
pN status, no., n = 186
No LN metastasis	154	Reference
With LN metastasis	32	1.027	0.418–2.525	0.954
Surgical margin, no., n = 180
Negative	152	Reference
Positive	28	1.539	0.716–3.305	0.269
Imaging parameters
miT status from PSMA PET, no., n = 186
2	125	Reference
≥ 3a	61	1.941	1.047–3.599	0.035
miN status from PSMA PET, no., n = 186
No LN metastasis	168	Reference
With LN metastasis	18	1.233	0.389–3.908	0.722
SUV_mean, no., n = 183
Continuous		0.743	0.491–1.123	0.159
SUV_max, no., n = 183
Continuous		1.202	0.943–1.532	0.137
TV
Continuous		0.934	0.883–0.988	0.017

BCR biochemical recurrence, CI confidence interval, iPSA initial PSA, LN lymph node, PET positron emission tomography, PSA prostate-specific antigen, PSMA prostate-specific membrane antigen, SUV standardized uptake value, TV tumor volume
*Significant associations are given in bold